furosemide has been researched along with Neoplasms in 45 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the effect of ultrasonically nebulized furosemide (20 mg) on dyspnea uncontrollable by standard therapy in patients with terminal cancer." | 7.72 | Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. ( Aoe, K; Kohara, H; Maeda, T; Saito, R; Shima, Y; Takeyama, H; Uchitomi, Y; Ueoka, H, 2003) |
| "Three terminal cancer patients with severe dyspnea were treated with nebulized furosemide." | 7.71 | Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. ( Shimoyama, M; Shimoyama, N, 2002) |
| " Diuresis using furosemide is effective in canines when maximally tolerated dosed cyclophosphamide is administered." | 5.46 | Furosemide for prevention of cyclophosphamide-associated sterile haemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide. ( Bunn, T; Ma, M; Setyo, L; Wang, P; Wyatt, K, 2017) |
| "Peripheral edema is a common feature in populations with advanced cancer, although it is seldom recognized." | 5.35 | High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients. ( David, F; Ferrera, P; Intravaia, G; Mercadante, S; Villari, P, 2009) |
| " Eight studies evaluated opioids in any route of administration, seven studies evaluated the use of oxygen, two studies assessed the role of benzodiazepines and two studies evaluated the role of furosemide in alleviating cancer-related dyspnea." | 4.88 | Interventions for alleviating cancer-related dyspnea: a systematic review and meta-analysis. ( Ben-Aharon, I; Gafter-Gvili, A; Leibovici, L; Stemmer, SM, 2012) |
| " In addition, characterization of the UGT1A locus and genetic studies directed at understanding the role of bilirubin glucuronidation and the biochemical basis of the clinical symptoms found in unconjugated hyperbilirubinemia have uncovered the structural gene polymorphisms associated with Crigler-Najjar's and Gilbert's syndrome." | 4.80 | Human UDP-glucuronosyltransferases: metabolism, expression, and disease. ( Strassburg, CP; Tukey, RH, 2000) |
| "We evaluated the effect of ultrasonically nebulized furosemide (20 mg) on dyspnea uncontrollable by standard therapy in patients with terminal cancer." | 3.72 | Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. ( Aoe, K; Kohara, H; Maeda, T; Saito, R; Shima, Y; Takeyama, H; Uchitomi, Y; Ueoka, H, 2003) |
| "The aim of this study was to evaluate the efficacy of noradrenaline and furosemide in combination for the treatment of impending acute renal failure in early stage of severe sepsis." | 3.72 | Renal rescue therapy in early stage of severe sepsis: a case study approach. ( Belovicova, C; Blaskova, A; Cintula, D; Setvak, D; Zahorec, R, 2004) |
| "Three terminal cancer patients with severe dyspnea were treated with nebulized furosemide." | 3.71 | Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. ( Shimoyama, M; Shimoyama, N, 2002) |
| "SIADH is underdiagnosed, and hospitalization often worsens the clinical situation, due to an iatrogenic excess in the use of oral and i." | 2.46 | [Current considerations in syndrome of inappropriate secretion of antidiuretic hormone/syndrome of inappropriate antidiuresis]. ( Runkle de la Vega, I; Velasco Cano, MV, 2010) |
| "This study proposes a new approach for cancer dual-target and proliferation inhibition by clustering multivalent receptors." | 1.72 | "Willow Branch" DNA Self-Assembly for Cancer Dual-Target and Proliferation Inhibition. ( Du, H; Wang, F; Wang, J; Zhang, R; Zhang, Z; Zhou, T, 2022) |
| "Edema of advanced cancer, seldom recognized in the literature, significantly impairs patient quality of life." | 1.51 | Edema of Advanced Cancer: Prevalence, Etiology, and Conservative Management-A Single Hospice Cross-Sectional Study. ( Gradalski, T, 2019) |
| " Diuresis using furosemide is effective in canines when maximally tolerated dosed cyclophosphamide is administered." | 1.46 | Furosemide for prevention of cyclophosphamide-associated sterile haemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide. ( Bunn, T; Ma, M; Setyo, L; Wang, P; Wyatt, K, 2017) |
| "Peripheral edema is a common feature in populations with advanced cancer, although it is seldom recognized." | 1.35 | High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients. ( David, F; Ferrera, P; Intravaia, G; Mercadante, S; Villari, P, 2009) |
| "Primary hyperparathyroidism and malignancy are responsible for greater than 90% of all cases of hypercalcemia." | 1.35 | Hypercalcemia: an evidence-based approach to clinical cases. ( Assadi, F, 2009) |
| "Fluconazole was used in 48% of the treatment episodes, amphotericin B in 46%, itraconazole in 4." | 1.34 | Drug-drug interactions with systemic antifungals in clinical practice. ( Abouelfath, A; Depont, F; Dupon, M; Dutronc, H; Galpérine, T; Giauque, E; Hébert, G; Moore, N; Ragnaud, JM; Valentino, R; Vargas, F, 2007) |
| " Mithramycin reliably induces a fall in serum calcium but long-term use is usually complicated by toxicity." | 1.27 | Therapy of malignancy-associated hypercalcemia: 1983. ( Stewart, AF, 1983) |
| "Furosemide was administered prior to, or 120 min after MMC." | 1.27 | Absence of interaction between furosemide and mitomycin C. ( de Vries, J; Kerpel-Fronius, S; Pinedo, HM; Stuurman, M; Verweij, J, 1987) |
| " The elimination half-life (t1/2 less than 80 min) allows autologous bone marrow transplantation 24 h after the drug administration." | 1.27 | Pharmacokinetics of high-dose melphalan in children and adults. ( Gouyette, A; Hartmann, O; Pico, JL, 1986) |
| "Forty patients with generalized cancer complicated by water and electrolyte retention were treated with "medium" and "large" doses of furosemide and bumetanide with 35% and 40% objective positive response, respectively." | 1.26 | Diuretics in malignant effusions and edemas of generalized cancer. ( Athanasiou, A; Dadiotis, L; Razis, DV, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (46.67) | 18.7374 |
| 1990's | 2 (4.44) | 18.2507 |
| 2000's | 12 (26.67) | 29.6817 |
| 2010's | 7 (15.56) | 24.3611 |
| 2020's | 3 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Tukey, RH | 1 |
| Strassburg, CP | 1 |
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Gharibkandi, NA | 1 |
| Molavipordanjani, S | 1 |
| Mardanshahi, A | 1 |
| Hosseinimehr, SJ | 1 |
| Gradalski, T | 1 |
| Clemens, E | 1 |
| de Vries, AC | 1 |
| Pluijm, SF | 1 |
| Am Zehnhoff-Dinnesen, A | 1 |
| Tissing, WJ | 1 |
| Loonen, JJ | 1 |
| van Dulmen-den Broeder, E | 1 |
| Bresters, D | 1 |
| Versluys, B | 1 |
| Kremer, LC | 1 |
| van der Pal, HJ | 1 |
| van Grotel, M | 1 |
| van den Heuvel-Eibrink, MM | 1 |
| Setyo, L | 1 |
| Ma, M | 1 |
| Bunn, T | 1 |
| Wyatt, K | 1 |
| Wang, P | 1 |
| Mercadante, S | 1 |
| Villari, P | 1 |
| Ferrera, P | 1 |
| David, F | 1 |
| Intravaia, G | 1 |
| Assadi, F | 1 |
| Velasco Cano, MV | 1 |
| Runkle de la Vega, I | 1 |
| Ben-Aharon, I | 1 |
| Gafter-Gvili, A | 1 |
| Leibovici, L | 1 |
| Stemmer, SM | 1 |
| Santoso, JT | 1 |
| Lucci, JA | 1 |
| Coleman, RL | 1 |
| Schafer, I | 1 |
| Hannigan, EV | 1 |
| Mank, A | 1 |
| Semin-Goossens, A | 1 |
| Lelie, Jv | 1 |
| Bakker, P | 1 |
| Vos, R | 1 |
| TOMAT, E | 2 |
| Kohara, H | 1 |
| Ueoka, H | 1 |
| Aoe, K | 1 |
| Maeda, T | 1 |
| Takeyama, H | 1 |
| Saito, R | 1 |
| Shima, Y | 1 |
| Uchitomi, Y | 1 |
| Zahorec, R | 1 |
| Setvak, D | 1 |
| Cintula, D | 1 |
| Belovicova, C | 1 |
| Blaskova, A | 1 |
| Mukoyama, M | 1 |
| Nakao, K | 1 |
| Depont, F | 1 |
| Vargas, F | 1 |
| Dutronc, H | 1 |
| Giauque, E | 1 |
| Ragnaud, JM | 1 |
| Galpérine, T | 1 |
| Abouelfath, A | 1 |
| Valentino, R | 1 |
| Dupon, M | 1 |
| Hébert, G | 1 |
| Moore, N | 1 |
| Cachia, E | 1 |
| Ahmedzai, SH | 1 |
| Stewart, AF | 1 |
| Amiel, SA | 1 |
| Blackburn, AM | 1 |
| Rubens, RD | 1 |
| Vogl, SE | 1 |
| Zaravinos, T | 1 |
| Kaplan, BH | 1 |
| Wollner, D | 1 |
| Bode, U | 1 |
| Seif, SM | 1 |
| Levine, AS | 1 |
| Rosenmund, A | 1 |
| Dana, R | 1 |
| Kachhwaha, VS | 1 |
| Shimoyama, N | 1 |
| Shimoyama, M | 1 |
| Fuchs, D | 1 |
| Hermann, J | 1 |
| Zintl, F | 1 |
| Plenert, W | 1 |
| Conte, N | 1 |
| Manente, P | 1 |
| valmachino, G | 1 |
| Gasparini, G | 1 |
| Lo Giudice, C | 1 |
| Fioretti, D | 1 |
| Gasparoni, P | 1 |
| Razis, DV | 1 |
| Athanasiou, A | 1 |
| Dadiotis, L | 1 |
| Tranchand, B | 1 |
| Ploin, YD | 1 |
| Minuit, MP | 1 |
| Sapet, C | 1 |
| Biron, P | 1 |
| Philip, T | 1 |
| Ardiet, C | 1 |
| Hasling, C | 1 |
| Charles, P | 1 |
| Mosekilde, L | 1 |
| Verweij, J | 1 |
| Kerpel-Fronius, S | 1 |
| Stuurman, M | 1 |
| de Vries, J | 1 |
| Pinedo, HM | 1 |
| Cirera, L | 1 |
| Gay, M | 1 |
| Tomé, T | 1 |
| Martí, M | 1 |
| Huguet, J | 1 |
| Plá, R | 1 |
| Gouyette, A | 1 |
| Hartmann, O | 1 |
| Pico, JL | 1 |
| Henness, AM | 1 |
| Kalter, S | 1 |
| Reeves, WB | 1 |
| Fillastre, JP | 1 |
| Humbert, G | 1 |
| Leroy, J | 1 |
| Verbanck, M | 1 |
| Futeral, B | 1 |
| Brauman, J | 1 |
| Ilunga, E | 1 |
| Borja, ER | 1 |
| Pugh, RP | 1 |
| Deftos, LJ | 1 |
| Neer, R | 1 |
| Walser, M | 1 |
| Wang, J | 1 |
| Zhang, Z | 1 |
| Zhang, R | 1 |
| Du, H | 1 |
| Zhou, T | 1 |
| Wang, F | 1 |
| Ward, JL | 1 |
| Wu, Y | 1 |
| Harflett, C | 1 |
| Onafuye, H | 1 |
| Corol, D | 1 |
| Lomax, C | 1 |
| Macalpine, WJ | 1 |
| Cinatl, J | 1 |
| Wass, MN | 1 |
| Michaelis, M | 1 |
| Beale, MH | 1 |
| Wick, JY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reliability and Utility of Fluid Balance Charting in Neonates Admitted to the Pediatric Ward.[NCT00962754] | Phase 4 | 170 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| (PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older[NCT01453088] | Phase 2 | 63 participants (Actual) | Interventional | 2010-06-24 | Terminated (stopped due to Lack of Accrual) | ||
| Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma[NCT01241708] | Phase 3 | 146 participants (Actual) | Interventional | 2010-04-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
notifications of complications (NCT00962754)
Timeframe: duration of admission
| Intervention | participants (Number) |
|---|---|
| Physician Insight Fluid Balance | 2 |
| Physician no Insight Fluid Balance Chart | 5 |
Duration of hospital stay in days or duration of admission at the pediatric ward in days (NCT00962754)
Timeframe: 1-8 months
| Intervention | number of days (Median) |
|---|---|
| Intervention Group (no Insight in Fluid Balance) | 9 |
| Control Group (Insight in Fluid Balance) | 8 |
prescription of diuretic therapy (NCT00962754)
Timeframe: during days of admission
| Intervention | participants (Number) |
|---|---|
| Intervention Group (no Insight in Fluid Balance) | 0 |
| Control Group (Insight in Fluid Balance) | 0 |
(NCT01453088)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 27 |
| Auto Transplant High Dose Melphalan+Bortezomib | 27 |
Progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib at 3 years (NCT01453088)
Timeframe: Participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 13 |
| Auto Transplant High Dose Melphalan+Bortezomib | 11 |
9 reviews available for furosemide and Neoplasms
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; | 2000 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
[Current considerations in syndrome of inappropriate secretion of antidiuretic hormone/syndrome of inappropriate antidiuresis].
Topics: Aging; Aquaporin 2; Arginine Vasopressin; Blood Volume; Brain Edema; Combined Modality Therapy; Diag | 2010 |
Interventions for alleviating cancer-related dyspnea: a systematic review and meta-analysis.
Topics: Analgesics, Opioid; Benzodiazepines; Dyspnea; Furosemide; Humans; Neoplasms; Oxygen; Palliative Care | 2012 |
[Syndrome of inappropriate secretion of antidiuretic hormone].
Topics: Central Nervous System Diseases; Chlorpropamide; Diagnosis, Differential; Furosemide; Humans; Inappr | 2006 |
[Hypercalcemia as an emergency].
Topics: Calcitonin; Calcium; Diphosphonates; Emergencies; Fluid Therapy; Furosemide; Humans; Hypercalcemia; | 1993 |
Medical management of the hypercalcemia of malignancy.
Topics: Bone Neoplasms; Calcitonin; Citrates; Edetic Acid; Ethacrynic Acid; Furosemide; Glucocorticoids; Hum | 1974 |
Treatment of hypercalcemias.
Topics: Administration, Oral; Calcitonin; Calcium, Dietary; Citrates; Diuretics; Edetic Acid; Ethacrynic Aci | 1970 |
Aspirin: a history, a love story.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzyl Alcohols; Cardiovascul | 2012 |
3 trials available for furosemide and Neoplasms
| Article | Year |
|---|---|
Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Creatinine; Diuretics; Drug Therapy, Com | 2003 |
Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Diuretics, | 1996 |
Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study.
Topics: Adult; Aged; Calcium; Clinical Trials as Topic; Double-Blind Method; Etidronic Acid; Female; Furosem | 1986 |
33 other studies available for furosemide and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
The Influence of Kidneys Ion Transport Inhibitors on the Pharmacokinetic and Tumor Uptake Behaviors of a HER2-targeted Small Size Radiolabeled Peptide.
Topics: Animals; Cations; Cimetidine; Furosemide; Humans; Ion Transport; Kidney; Mice; Mice, Nude; Neoplasms | 2022 |
Edema of Advanced Cancer: Prevalence, Etiology, and Conservative Management-A Single Hospice Cross-Sectional Study.
Topics: Aged; Conservative Treatment; Cross-Sectional Studies; Diuretics; Drainage; Edema; Extremities; Fema | 2019 |
Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Audiometry, Pure-Tone; Carboplatin; Child; Ch | 2016 |
Furosemide for prevention of cyclophosphamide-associated sterile haemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide.
Topics: Administration, Metronomic; Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cystitis; | 2017 |
High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients.
Topics: Aged; Aged, 80 and over; Diuretics; Edema; Female; Furosemide; Humans; Infusions, Intravenous; Leg; | 2009 |
Hypercalcemia: an evidence-based approach to clinical cases.
Topics: Anti-Inflammatory Agents; Diuretics; Evidence-Based Medicine; Fluid Therapy; Furosemide; Humans; Hyp | 2009 |
Monitoring hyperhydration during high-dose chemotherapy: body weight or fluid balance?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Body Water; Body Weight; Cohort Studies; Confounding | 2003 |
[ON CLINICAL APPLICATIONS OF FUROSEMIDE].
Topics: Ascites; Diuretics; Edema; Furosemide; Humans; Neoplasms | 1965 |
[ON CLINICAL APPLICATIONS OF FUROSEMIDE].
Topics: Ascites; Diuretics; Edema; Furosemide; Humans; Neoplasms | 1965 |
Effect of nebulized furosemide in terminally ill cancer patients with dyspnea.
Topics: Chloride Channels; Critical Illness; Dyspnea; Furosemide; Humans; Nebulizers and Vaporizers; Neoplas | 2003 |
Renal rescue therapy in early stage of severe sepsis: a case study approach.
Topics: Acute Kidney Injury; Adult; Aged; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; | 2004 |
Drug-drug interactions with systemic antifungals in clinical practice.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Creatinine; Cyclosporine; Drug Interactions; Female; | 2007 |
Breathlessness in cancer patients.
Topics: Administration, Inhalation; Analgesics, Opioid; Benzodiazepines; Bronchodilator Agents; Chemorecepto | 2008 |
Therapy of malignancy-associated hypercalcemia: 1983.
Topics: Administration, Oral; Adult; Bone Neoplasms; Bone Resorption; Calcitonin; Calcium; Child; Diphosphon | 1983 |
Intravenous infusion of frusemide as treatment for ascites in malignant disease.
Topics: Adult; Aged; Ascites; Female; Furosemide; Humans; Infusions, Parenteral; Middle Aged; Neoplasms | 1984 |
Safe and effective two-hour outpatient regimen of hydration and diuresis for the administration of cis-diamminedichloroplatinum (II).
Topics: Adult; Aged; Ambulatory Care; Cisplatin; Diuresis; Female; Fluid Therapy; Furosemide; Humans; Male; | 1981 |
Studies on the antidiuretic effect of cyclophosphamide: vasopressin release and sodium excretion.
Topics: Adolescent; Adult; Child; Cyclophosphamide; Diuresis; Drug Therapy, Combination; Female; Furosemide; | 1980 |
Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients.
Topics: Administration, Inhalation; Diuretics; Dyspnea; Furosemide; Humans; Male; Middle Aged; Nebulizers an | 2002 |
[Basic therapy in children with leukemia and a malignant tumors. II].
Topics: Allopurinol; Anaphylaxis; Anemia; Antibiotics, Antineoplastic; Bicarbonates; Blood Transfusion; Chil | 1978 |
[Therapy of neoplastic hypercalcemia].
Topics: Aged; Calcitonin; Female; Furosemide; Humans; Hypercalcemia; Isotonic Solutions; Male; Middle Aged; | 1978 |
Diuretics in malignant effusions and edemas of generalized cancer.
Topics: Ascites; Body Weight; Bumetanide; Diuretics; Drinking; Edema; Furosemide; Humans; Neoplasms; Pleuris | 1976 |
High-dose melphalan dosage adjustment: possibility of using a test-dose.
Topics: Adolescent; Adult; Child; Child, Preschool; Furosemide; Humans; Melphalan; Metabolic Clearance Rate; | 1989 |
Absence of interaction between furosemide and mitomycin C.
Topics: Adult; Drug Interactions; Female; Furosemide; Humans; Kidney; Kinetics; Male; Middle Aged; Mitomycin | 1987 |
[Administration of high doses of cisplatin in 20-minute infusions].
Topics: Cisplatin; Fluid Therapy; Furosemide; Humans; Infusions, Intravenous; Kidney Diseases; Mannitol; Neo | 1988 |
Pharmacokinetics of high-dose melphalan in children and adults.
Topics: Adolescent; Adult; Carmustine; Child; Child, Preschool; Diuresis; Dose-Response Relationship, Drug; | 1986 |
Pharmacokinetics of high-dose melphalan in children and adults.
Topics: Adolescent; Adult; Carmustine; Child; Child, Preschool; Diuresis; Dose-Response Relationship, Drug; | 1986 |
Pharmacokinetics of high-dose melphalan in children and adults.
Topics: Adolescent; Adult; Carmustine; Child; Child, Preschool; Diuresis; Dose-Response Relationship, Drug; | 1986 |
Pharmacokinetics of high-dose melphalan in children and adults.
Topics: Adolescent; Adult; Carmustine; Child; Child, Preschool; Diuresis; Dose-Response Relationship, Drug; | 1986 |
Treatment of cyclophosphamide-induced cystitis.
Topics: Animals; Cat Diseases; Cats; Cyclophosphamide; Cystitis; Dog Diseases; Dogs; Female; Furosemide; Mal | 1985 |
Hypernatremia in cancer patients receiving normal saline, furosemide, and "salt-poor" albumin.
Topics: Aged; Drug Therapy, Combination; Furosemide; Humans; Hypernatremia; Male; Middle Aged; Neoplasms; Se | 1985 |
Treatment of acute hypercalcemia with furosemide.
Topics: Acute Disease; Adult; Aged; Calcium; Diuresis; Female; Furosemide; Humans; Hypercalcemia; Male; Midd | 1973 |
[Diagnosis and treatment of hypercalcemia].
Topics: Acromegaly; Adrenal Insufficiency; Adult; Aged; Calcinosis; Calcitonin; Cortisone; Edetic Acid; Fema | 1973 |
Management of hypercalcemia secondary to malignancy.
Topics: Adrenal Cortex Hormones; Edetic Acid; Furosemide; Humans; Hypercalcemia; Neoplasms; Phosphates; Plic | 1974 |
"Willow Branch" DNA Self-Assembly for Cancer Dual-Target and Proliferation Inhibition.
Topics: Antibodies; Aptamers, Nucleotide; beta Catenin; Cell Proliferation; DNA; DNA, Single-Stranded; Human | 2022 |
Miyabeacin: A new cyclodimer presents a potential role for willow in cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Benzyl Alcohols; Biosynthetic Pathways; Cell Line, Tumor; Drug Sc | 2020 |